Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Swenerton

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Cancer Treatment Reviews|January 1, 1993
Preliminary evaluation of a multicenter, randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Canadian-European Taxol Cooperative Trial GroupW W ten Bokkel Huinink, E Eisenhauer, K Swenerton
The Journal of Laboratory and Clinical Medicine|January 1, 1991
Chronic hypomagnesemia caused by cisplatin: effect of calcitriolR A Sutton, V R Walker, A Halabe, et al.
The Journal of Biological Chemistry|August 3, 2010
Leishmania subtilisin is a maturase for the trypanothione reductase system and contributes to disease pathologyRyan K Swenerton, Giselle M Knudsen, Mohammed Sajid, et al.
Obstetrics and Gynecology|March 1, 1988
Toxicity of abdominopelvic radiation in advanced ovarian carcinoma patients after cisplatin/cyclophosphamide therapy and second-look laparotomyW E Shelley, A A Starreveld, J A Carmichael, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 1, 1996
A phase I study of bi-weekly paclitaxel/cisplatin as initial therapy for advanced ovarian cancer. A study of the National Cancer Institute of Canada Clinical Trials GroupK Swenerton, P Hoskins, G Stuart, et al.
Gynecologic Oncology|July 22, 2010
A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149)H Hirte, A Oza, K Swenerton, et al.
Cancer Treatment Reports|May 1, 1987
High-dose-intensity regimen of weekly doxorubicin and cisplatin in the treatment of patients with stage III and IV epithelial ovarian carcinomaG O'Connell, W Shelley, J Carmichael, et al.
AIDS Research and Human Retroviruses|August 25, 2000
Sensitive and robust one-tube real-time reverse transcriptase-polymerase chain reaction to quantify SIV RNA load: comparison of one- versus two-enzyme systemsR Hofmann-Lehmann, R K Swenerton, V Liska, et al.
The Journal of Biological Chemistry|October 22, 2010
The oligopeptidase B of Leishmania regulates parasite enolase and immune evasionRyan K Swenerton, Shuyi Zhang, Mohammed Sajid, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1992
Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials GroupK Swenerton, J Jeffrey, G Stuart, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Cancer Treatment Reviews|January 1, 1993
Preliminary evaluation of a multicenter, randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Canadian-European Taxol Cooperative Trial GroupW W ten Bokkel Huinink, E Eisenhauer, K Swenerton
The Journal of Laboratory and Clinical Medicine|January 1, 1991
Chronic hypomagnesemia caused by cisplatin: effect of calcitriolR A Sutton, V R Walker, A Halabe, et al.
The Journal of Biological Chemistry|August 3, 2010
Leishmania subtilisin is a maturase for the trypanothione reductase system and contributes to disease pathologyRyan K Swenerton, Giselle M Knudsen, Mohammed Sajid, et al.
Obstetrics and Gynecology|March 1, 1988
Toxicity of abdominopelvic radiation in advanced ovarian carcinoma patients after cisplatin/cyclophosphamide therapy and second-look laparotomyW E Shelley, A A Starreveld, J A Carmichael, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 1, 1996
A phase I study of bi-weekly paclitaxel/cisplatin as initial therapy for advanced ovarian cancer. A study of the National Cancer Institute of Canada Clinical Trials GroupK Swenerton, P Hoskins, G Stuart, et al.
Gynecologic Oncology|July 22, 2010
A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149)H Hirte, A Oza, K Swenerton, et al.
Cancer Treatment Reports|May 1, 1987
High-dose-intensity regimen of weekly doxorubicin and cisplatin in the treatment of patients with stage III and IV epithelial ovarian carcinomaG O'Connell, W Shelley, J Carmichael, et al.
AIDS Research and Human Retroviruses|August 25, 2000
Sensitive and robust one-tube real-time reverse transcriptase-polymerase chain reaction to quantify SIV RNA load: comparison of one- versus two-enzyme systemsR Hofmann-Lehmann, R K Swenerton, V Liska, et al.
The Journal of Biological Chemistry|October 22, 2010
The oligopeptidase B of Leishmania regulates parasite enolase and immune evasionRyan K Swenerton, Shuyi Zhang, Mohammed Sajid, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1992
Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials GroupK Swenerton, J Jeffrey, G Stuart, et al.
Pageof 2